Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 5-6/2009

01-12-2009 | Breast Cancer

Maintaining Fertility in Young Women with Breast Cancer

Authors: Melissa C. Hulvat, MD, Jacqueline S. Jeruss, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 5-6/2009

Login to get access

Opinion statement

Breast cancer effects nearly 200,000 American women each year, with 9% of these women still in their childbearing years. For this subset of future survivors, the issue of fertility may be a significant quality-of-life concern. Both the causes and treatments for infertility in young breast cancer patients must be thoroughly understood by the multidisciplinary team caring for these women in order for the caregivers to be effective advocates for their patients. Radiation, cytotoxic chemotherapy, and hormonal therapy all effect ovarian function to greater or lesser degrees, with the incidence of permanent post-treatment amenorrhea following systemic treatment for breast cancer in women age 50 or younger estimated as between 33% and 76%. The science of fertility preservation continues to experience significant advances in terms of the success of oocyte, embryo, and ovarian tissue preservation, and it is crucial that physicians and patients are aware of the available fertility preservation options. The optimal time to address the possibility of treatment-related infertility and strategies to combat this with younger patients is prior to treatment, rather than after cancer therapy has begun, and a full knowledge of the available technologies is a prerequisite for an informed discussion. Causes of ovarian suppression and options for treatment, including consideration of preimplantation genetic diagnosis and alternative parenting approaches are also discussed to assist the clinician caring for young patients with cancer.
Literature
1.
Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996,14(5):1718–1729.PubMed
2.
4.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43–66.CrossRefPubMed
5.
ACS. Breast Cancer Facts & Figures 2007–2008. Report. Atlanta, GA: American Cancer Society, Inc.; 2008
6.
Lee SJ, Schover LR, Partridge AH, et al.: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24(18):2917–2931.CrossRefPubMed
7.
Partridge AH, Gelber S, Peppercorn J, et al.: Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004, 22(20):4174–4183.CrossRefPubMed
8.
Falcone T, Attaran M, Bedaiwy MA, Goldberg JM: Ovarian function preservation in the cancer patient. Fertil Steril 2004, 81(2):243–257.CrossRefPubMed
9.
Meirow D, Nugent D: The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001, 7(6):535–543.CrossRefPubMed
10.
Maltaris T, Seufert R, Fischl F, et al.: The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007, 130(2):148–155.CrossRefPubMed
11.
Wallace WH, Thomson AB, Saran F, Kelsey TW: Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005, 62(3):738–744.PubMed
12.
Critchley HO, Wallace WH, et al.: Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005, 34:64–68.CrossRefPubMed
13.
Fenig E, Mishaeli M, Kalish Y, Lishner M: Pregnancy and radiation. Cancer Treat Rev 2001, 27(1):1–7.CrossRefPubMed
14.
Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N, Gourtsoyiannis N: Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys 2003, 55(2):386–391.PubMed
15.
Antypas C, Sandilos P, Kouvaris J, et al.: Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998, 40(4):995–999.CrossRefPubMed
16.
Lutchman Singh K, Muttukrishna S, Stein RC, et al.: Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007, 96(12):1808–1816.CrossRefPubMed
17.
Visser JA, Themmen AP: Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005, 234(1–2):81–86.CrossRefPubMed
18.
Anders C, Marcom PK, Peterson B, et al.: A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008, 26(3):286–295.CrossRefPubMed
19.
Sonmezer M, Oktay K: Fertility preservation in female patients. Hum Reprod Update 2004, 10(3):251–266.CrossRefPubMed
20.
Petrek JA, Naughton MJ, Case LD, et al.: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24(7):1045–1051.CrossRefPubMed
21.••
Maltaris T, Weigel M, Mueller A, et al.: Cancer and fertility preservation: fertility preservation in breast cancer patients. Breast Cancer Res 2008, 10(2):206.CrossRefPubMed
22.
Halakivi-Clarke L, Cho E, Onojafe I, Liao DJ, Clarke R: Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring. Clin Cancer Res 2000, 6(1):305–308.PubMed
23.
24.
Gradishar WJ, Hellmund R: A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2002, 2(4):282–286.CrossRefPubMed
25.
Arnon J, Meirow D, Lewis-Roness H, Ornoy A: Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001,7(4):394–403.CrossRefPubMed
26.
Partridge AH, Ruddy KJ: Fertility and adjuvant treatment in young women with breast cancer. The Breast 2007, 16(Suppl 2):175–181.CrossRef
27.••
Lobo RA: Potential options for preservation of fertility in women. N Engl J Med 2005, 353(1):64–73.CrossRefPubMed
28.
Recchia F, Saggio G, Amiconi G, et al.: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006, 106(3):514–523.CrossRefPubMed
29.
Ambrosone GB, Barlow W, Yeh I-T, et al.: Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a southwest oncology intergroup trial (INT-0102). Cancer 2006, 100:S18.
30.
Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE: Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008, 110(3):411–416.CrossRefPubMed
31.
Cahill DJ, Wardle PG, Harlow CR, Hunt LP, Hull MG: Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum Reprod 2000, 15(9):1909–1912.CrossRefPubMed
32.
Gupta PB, Kuperwasser C: Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006, 102(1–5):71–78.CrossRefPubMed
33.
Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z: Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003, 18(1):90–95.CrossRefPubMed
34.
Oktay K: Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005, 23(16):3858–3859.CrossRefPubMed
35.
Azim AA, Costantini-Ferrando M, Oktay K: Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008, 26(16):2630–2635.CrossRefPubMed
36.
Madrigrano A, Westphal L, Wapnir I: Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg 2007, 194(4):477–481.CrossRefPubMed
37.
Stachecki JJ, Cohen J: An overview of oocyte cryopreservation. Reprod Biomed Online 2004, 9(2):152–163.PubMedCrossRef
38.
Tao T, Del Valle A: Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet 2008, 25(7):287–296.CrossRefPubMed
39.
Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S: Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes 2008, 15(6):529–535.PubMed
40.
Backhus LE, Kondapalli LA, Chang RJ, Coutifaris C, Kazer R, Woodruff TK: Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. Cancer Treat Res 2007, 138:235–239.CrossRefPubMed
41.
Sanchez M, Novella-Maestre E, Teruel J, Ortiz E, Pellicer A: The Valencia programme for fertility preservation. Clin Transl Oncol 2008, 10(7):433–438.CrossRefPubMed
42.
Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y: Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 2007, 12(12):1437–1442.CrossRefPubMed
43.
Donnez J, Dolmans MM, Demylle D, et al.: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004, 364(9443):1405–1410.CrossRefPubMed
44.
Meirow D, Levron J, Eldar-Geva T, et al.: Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005, 353(3):318–321.CrossRefPubMed
45.
Woodruff TK, Shea LD: The role of the extracellular matrix in ovarian follicle development. Reprod Sci 2007, 14(8 Suppl):6–10.CrossRefPubMed
46.•
Xu M, Woodruff TK, Shea LD: Bioengineering and the ovarian follicle. Cancer Treat Res 2007, 138:75–82.CrossRefPubMed
47.
Telfer EE, McLaughlin M, Ding C, Thong KJ: A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod 2008, 23(5):1151–1158.CrossRefPubMed
48.
Xu M, Kreeger PK, Shea LD, Woodruff TK: Tissue-engineered follicles produce live, fertile offspring. Tissue Eng 2006, 12(10):2739–2746.CrossRefPubMed
49.
Verlinsky Y, Cohen J, Munne S, et al.: Over a decade of experience with preimplantation genetic diagnosis: a multicenter report. Fertil Steril 2004, 82(2):292–294.CrossRefPubMed
50.
Offit K, Kohut K, Clagett B, et al.: Cancer genetic testing and assisted reproduction. J Clin Oncol 2006, 24(29):4775–4782.CrossRefPubMed
51.
Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM: Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 2008, 7(2):179–186.CrossRefPubMed
52.
Menon SJ: Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008, 277(1):1–13.CrossRefPubMed
53.•
Rosen A: Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005, 34:91–93.CrossRefPubMed
Metadata
Title
Maintaining Fertility in Young Women with Breast Cancer
Authors
Melissa C. Hulvat, MD
Jacqueline S. Jeruss, MD, PhD
Publication date
01-12-2009
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 5-6/2009
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-010-0116-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits